Kelly White

Kelly White, PharmD, is Vice President of Clinical and Medical Affairs of Fractyl Health. Kelly has more than 15 years of pharmaceutical and biotechnology experience in clinical development and global medical affairs, with focused expertise in building/expanding field and headquarters medical teams, establishing strategic plans, medical communications, publication plans, and the global launching of products.

Prior to Fractyl, she served as Executive Director of Global Medical Affairs at Intercept, where the focused effort was the obeticholic acid development programs that resulted in the first approval in ~20 years for patients with primary biliary cholangitis (PBC) and the program in NASH that resulted in the first positive Phase 3 trial in this disease.

Prior to joining Intercept, she held positions of increasing responsibility in large pharma at AbbVie, Abbott, and AstraZeneca focusing on pre-launch, launch, and post-launch in a variety of medical affairs responsibilities in multiple products.

Kelly holds a doctorate degree in Pharmacy from Northeastern University with a specialty in Infectious Diseases Pharmacotherapy.